Pharmaceutical Executive-02-01-2022

Digital disruption is poised to usher in a new era of customer-centricity and efficiency, starting with trials and precision targeting.

Our latest CEO Leadership roundtable focused on the most top-of-mind issues for companies.

Designing an omnichannel artificial intelligence ecosystem that integrates strategies can boost commercial success for pharma.

Pharma should take an integrated approach to representing cultural elements in materials.

Industry embraces modern approach to commercialization, but keeps human connection at center.

Ted Schroeder, CEO of Nabriva Therapeutics, is passionate in his forward-thinking approach to finding the next generation of anti-infectives, as resistance to least-expensive, tried-and-true therapies continues to grow.

Biopharma stock performance continues to struggle.

Payers not looking to favor one product.

Spurred on by COVID-19 and companies’ evolving digital maturity, AI looks set to gain a real foothold in pharma’s promotional activities.

Addressing whole employee is as important as treating whole patient.

European Commission looks to relieve issues without legislation.

Assessing the value of industry.

Click the title above for a link to open the Pharmaceutical Executive February 2022 issue in an interactive PDF format.

International collaboration needed to address distribution hurdles.